Medisun Precision Medicine Ltd. (fka MPME)

[ktcougar]

The purpose of the transaction and First License Agreement was to give Issuer the non-exclusive right to use the NK cell technology subject to certain conditions for 10 years in the United States and Greater China in exchange for the Reporting Person receiving 10,000,000 shares or 51.6% of the Issuer’s issued and outstanding common stock as of April 18, 2017. Concurrent to the License Agreement, Bryan Lee, Stefan Moll, and Oliver Jackson resigned their positions as directors and officers of
Issuer, and Issuer’s Board of Directors appointed Ms. Sophia Yaqi Sun as President, Chief Executive Officer, Chief Financial Officer, and Director. The Board of Directors also appointed Ms. Lisha Huang as Director. Pursuant to the License Agreement, the Issuer obtained the requisite approval to increase its authorized number of Common Stock to 100,000,000 shares. Issuer plans to acquire a controlling interest in a subsidiary of Medisun Holdings Limited. The purpose of the Second License Agreement was to expand the licensed regions to the rest of the world (i.e. other than the Greater China and the United States) in exchange for the Reporting Person receiving 30,000,000 shares of the Issuer’s common stock.
http://ih.advfn.com/p.php?pid=nmona&article=74982935

Some info on Ms. Yaqi Sun:
Prior to joining Medisun and NIF, Ms. Sun has worked for Ernest & Young LLP in Beijing and San Francisco, leading audit teams in financial auditing, bad debt evaluation, merger acquisition due diligence for commercial banks. Ms. Sun has obtained her Bachelor's degree at University of International Business and Economics in the People's Republic of China and her Master of Business Administration degree at the University of Illinois.

kt